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SRC-3 是核激素受体（包括雄激素雌激素受体和其他一些转录因子如 E2F1 and 
NF-κB）转录辅激活子 p160 家族一员。SRC-3 在多种癌症（例如乳腺癌、前列
腺癌﹑胰腺癌、胃癌和肝癌 ）中过量表达。但是 SRC-3 在结肠癌细胞增殖过
程中所起的作用还不太清楚。本研究中，我们发现在结肠癌细胞RKO和LS-174T
中通过 shRNA 将 SRC-3 敲减，能够抑制癌细胞的增殖、平板克隆的形成和细
胞周期。这些由 SRC-3 敲减引起的表型变化与 Cyclin A2 和 Cyclin E2 的 mRNA
水平的降低和细胞周期抑制因子 P27 mRNA 水平的升高相关联。此外，我们发
现 HES1 mRNA 的水平是降低的，而 ATOH1 和 MUC2 mRNA 水平升高。HES1
蛋白属于螺旋-环-螺旋转录因子家族成员，HES1 通过抑制 p27 来调节细胞周期
循环。ATOH1 和 MUC2 受 Notch-HES1 信号通路的调节。ATOH1 是一种螺旋-
环-螺旋转录因子，它对肠道分泌细胞有着重要作用，同时被认为在 Notch 信号
通路中起着一定作用。MUC2 能够编码一种特殊的分泌粘液素，这种粘液素主
要在结直肠的杯状细胞中表达。SRC-3 敲减可能是通过上调 ATOH1、MUC2 这
些基因来促使结直肠癌细胞的分化。之前的这些结果说明 SRC-3 可能通过影响
Notch 信号通路进而对结肠癌细胞的增殖起着正调控作用。  
 


















Colon cancer is the third most prevalent form of cancer in the occidental world for 
both men and women, and accounts for 10% of new cancer cases and 10% of cancer 
deaths. Steroid receptor coactivator-3 (SRC-3, p/CIP, AIB1, ACTR, RAC3, and 
TRAM-1) is a member of the p160 family of coactivators for nuclear hormone 
receptors such as estrogen and androgen receptor, and other transcription factors such 
as E2F1 and NF-κB. SRC-3 is frequently amplified or overexpressed in a number of 
cancers such as breast, prostate, pancreas, stomach and colon cancer. However, the 
role of SRC-3 in colon cancer cells proliferation has not been investigated. In this 
study, we showed that knockdown of SRC-3 expression by small hairpin RNA in 
colon cancer cells RKO and LS-174T, caused decreased colon cancer cells 
proliferation, colony formation and inhibited cell cycle progression. These phenotypic 
changes caused by SRC-3 knockdown correlated with decreased mRNA levels of 
cyclinA2/E2, and increased mRNA level of the cell cycle inhibitor p27. In addition, 
HES1 expression was decreased. HES1 (hairy and enhancer of split) protein belongs 
to the basic helix-loop-helix family of transcription factors. HES1 regulates the cell 
cycle by inhibiting p27. ATOH1 and MUC2 were reported to be under control of 
Notch-HES1 pathway. The mRNA levels of ATOH1 and MUC2, which are gene 
markers of differenciation, were increased. ATOH1 is basic helix-loop-helix 
transcription factor, is required for intestinal secretory cells and is considered part of 
the Notch pathway. The MUC2 gene codes for a typical secretory mucin, which is 
predominantly found in colorectal goblet cells. These findings also suggest that 
knockdown of SRC-3 promotes differenciation by up-regulation of MUC2 and 
ATOH1, which are target genes of Notch pathway. Taken together, these findings 
indicate that SRC-3 is a positive regulator of colon cancer cells proliferation and may 
have a possible link with the Notch pathway. 

















Abstract in Chinese ................................................................................... I 
Abstract in English ................................................................................. II 
CHAPTER 1 INTRODUCTION .............................................................1 
1.1 P160 family ................................................................................... 1 
1.1.1 Discovery of SRCs ......................................................................................... 1 
1.1.2 Organization and expression of the SRC-3 gene ........................................... 2 
1.1.3 Molecular structure and functional features of SRCs .................................... 3 
1.1.4 SRC-3 in cancer ............................................................................................. 7 
1.1.5 Molecular mechanisms of SRC-3 function .................................................. 10 
1.1.5.1 Hormone-dependent signal transduction pathway ................................ 10 
1.1.5.2 Hormone-independent signal transduction pathway ............................. 10 
1.1.5.2.1 E2F1 signal pathway .......................................................................... 10 
1.1.5.2.2 Insulin-like growth factor-1/AKT signal pathway Insulin ................. 11 
1.1.5.2.3 NF-κB signal pathway  ...................................................................... 12 
1.1.5.2.4 CCAAT/enhancer-binding protein beta (C/EBPβ)signal pathway ..... 13 
1.1.5.2.5 HER2/neu/MAPK signal pathway ..................................................... 14 
1.1.6 Post-modification and regulation of SRC-3 ................................................. 15 
1.1.6.1 Phosphorylation ..................................................................................... 15 
1.1.6.2 Ubiquitylation ........................................................................................ 16 
1.1.6.3 Sumoylation ........................................................................................... 17 
1.1.6.4 Acetylation and methylation .................................................................. 17 
1.1.6.5 Combined post-translational modifications ........................................... 18 
1.2 Cell cycle ............................................................................................................ 18 
1.2.1 Cyclins ......................................................................................................... 20 
1.2.2 Cyclin-dependent kinases (CKDs) ............................................................... 21 
1.2.2.1 CDK substrates ......................................................................................... 21 















1.2.4 Cell cycle and cancer ................................................................................... 23 
1.3 Notch pathway .................................................................................................. 25 
1.3.1 The basics of Notch signaling  .................................................................... 25 
1.3.2 Notch pathway and cancer ........................................................................... 27 
1.4 thesis structure .................................................................................................. 30 
1.5 Research aims and objectives .......................................................................... 30 
CHAPTER 2 MATERIALS AND METHODS ....................................32 
2.1 Materials ..................................................................................... 32 
2.1.1 Plamids, Bacterium, Cell lines ..................................................................... 32 
2.1.2 Reagents ....................................................................................................... 32 
2.1.3 Equipments .................................................................................................. 33 
2.2 Methods ............................................................................................................. 34 
2.2.1 Making competent cells ............................................................................... 34 
2.2.2 Restriction enzyme digest ............................................................................ 35 
2.2.3 Agarose gel electrophoresis and gel purification ......................................... 35 
2.2.4 Construction of Plasmid Expressing shRNA for SRC-3 .............................. 36 
2.2.5. Transformation ............................................................................................ 37 
2.2.6 Plasmid purification  ................................................................................... 37 
2.2.7 Cell culture and generating stable transfectants ........................................... 38 
2.2.8 Western blot ................................................................................................. 39 
2.2.8.1 Protein extraction ................................................................................. 39 
2.2.8.2 Determination of protein concentration  (BCA assay) ........................ 40 
2.2.8.3 Electrophoresis of proteins in SDS-page gel and western blot ............. 41 
2.2.9 Colony formation ......................................................................................... 42 
2.2.10 MTT ........................................................................................................... 43 
2.2.11 Flow cytometry .......................................................................................... 43 
2.2.12 Real-time PCR ........................................................................................... 44 
2.2.12.1The mRNA extraction........................................................................... 44 
2.2.12.2 Reverse transcription of cDNA  ......................................................... 45 















CHAPTER 3 RESULTS .........................................................................48 
3.1 Dowregulation of SRC-3 in colon cancer cells .................................................. 48 
3.2 Downregulation of SRC-3 inhibits colon cancer cells growth ........................... 49 
3.3 Downregulation of SRC-3 inhibits colony formation in colon cancer cells ...... 50 
3.4 Downregulation of SRC-3 inhibits the cell cycle progression in conlon cancer 
cells ................................................................................................................... 51 
3.5 SRC-3 is required for the expression of genes related to cell cycle ................... 52 
3.6 Knockdown SRC-3 promotes differenciation of colon cells. ........................ 54 
CHAPTER 4 DISCUSSION ..................................................................56 




























LIST OF TABLES AND FIGURES 
VI 
 
LIST OF TABLES AND FIGURES 
 
Table 1 List of proteins that interact with SRCs ........................................................ 6 
Table 2 Mammalian cyclins ..................................................................................... 21 
Table 3 Sequences of the primers ............................................................................ 46 
Figure 1 Organization of the human SRC-3 gene ..................................................... 3 
Figure 2 Structural and funtional domains of the mouse SRC-3 protein .................. 4 
Figure 3 SRC-3 integrates with multiple signal pathways ...................................... 14 
Figure 4 The stages of the cell cycle by CDKIs ...................................................... 19 
Figure 5 Regulation of cell cycle by CDKIs ........................................................... 23 
Figure 6 The Notch signaling cascade ..................................................................... 27 
Figure 7 Downregulation of SRC-3 by sh-RNA in colon cell lines (RKO and 
LS-174T) .................................................................................................. 48 
Figure 8 Knocddown of SRC-3 reduced proliferation rate of RKO and LS-174T as 
measured by MTT .................................................................................... 49 
Figure 9 Downregulation of SRC-3 reduces colony formation of colon cancer 
cells RKO and LS-174T ........................................................................... 51 
Figure 10 Cell cycle analysis by flow cytometry .................................................... 52 
Figure 11 Real-time PCR analysis of mRNA levels of different genes .............. 53/54 














Chapter 1 Introduction 
 1
CHAPTER 1 INTRODUCTION 
1.1 P160 Family: 
1.1.1 Discovery of co-activators: 
Steroid hormones, thyroid hormones (THs), retinoids, vitamin D, prostaglandins, and 
bile acids play pivotal roles in the regulation of a variety of developmental events and 
physiological functions. The biological activities of these hormones and bioactive 
metabolites are mediated by their cognate nuclear receptors (NRs), which are 
ligand-dependent and DNA sequence-specific transcription factors(1). They can 
regulate gene expression  positively or negatively by interacting with specific DNA 
sequences(2). 
The journey to understand how NRs control gene transcription has been long and 
difficult. Initially, it was thought that NRs enabled general transcription factors and 
RNA polymerase II to assemble at the gene promoter to initiate mRNA synthesis. In 
1969, Britten and Davidson presented a theory that within the genome there is a 
subgroup of genes that act as master genes to implement coordinate expression of 
other subservient genes termed “producer genes.” They considered these master genes 
to be RNAs that directly regulate transcription. However, work began in the 1970s to 
search for nuclear non-histone helper proteins that were thought to aid the binding to 
DNA and the transcriptional function of NRs(3-4). The findings that the activation of 
one overexpressed NR could indirectly inhibit the transcriptional activity of another 
NR and that in vitro transcription systems consisting of purified NRs and general 
transcription factors were inefficient further suggested that additional transcription 
activators were required for efficient hormone-induced transcriptional activation(5).  
In 1995, steroid receptor co-activator 1 (SRC-1, also known as NCOA1) was finally 
cloned From this point forward, recruitment of coactivators was accepted as the 
mechanism for the gene-inductive function of NRs, and the following criteria for 
coactivators were substantiated: 1) coactivators bind to NRs (directly or indirectly); 2) 
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binding to NRs; 4) antagonist ligands inhibit binding of coactivators to receptors; 5) 
overexpression of coactivators greatly enhances transcriptional capacity; and 7) 
coactivator dominant-negative molecules knock down endogenous ligand-dependent 
NR function when introduced into cells(3). 
SRC-1 was found to interact with steroid receptors in a hormone-dependent manner 
and robustly increase the transcriptional activities of steroid receptors. Soon after, two 
other homologous proteins, SRC-2 (also known as TIF2 GRIP1 and NCOA2) (6-7) , 
and SRC-3 (also known as p/CIP, RAC3, AIB1, ACTR, TRAM1 and NCOA3) (8) , 
were characterised as NR coactivators. These  proteins  encoded by SRC gene 
family are about 160 KDa in size and  have an overall sequence similarity of about 
40%  between them (9). 
1.1.2 Organization and expression of the SRC-3 gene： 
The mouse SRC-3 gene is located in the H2–H4 region of chromosome 2 and consists 
of 20 exons. The entire gene is about 40 kb in length with introns 1 (13.5 kb) and 15 
(4.6 kb) contributing approximately half of its entire length. The start and stop codons 
for translation are located in exons2 and 20, respectively (10).  The human SRC-3 
gene is located in chromosomal region 20q12 (11). According to a cDNA sequence 
(GenBank accession number AF012108) and two human genomic DNA sequences 
(GenBank accession numbers HS237J2 and HS1049G16), the structure of the human 
SRC-3 gene is illustrated in (Figure 1). The organization of the human SRC-3 gene is 
more complicated. It is about 75 kb in length and contains as many as 22 exons. The 
largest intron, intron 1, is more than 40 kb in length. The translational start and stop 
codons are located in exons 2 and 22, respectively. SRC-3 isoforms can be produced 
through alternative splicing of these exons. For example, an isoform that excluded 
exon 3 was detected in breast cancer cells and its overexpression was able to increase 
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Figure 1: Organization of the human SRC-3 gene. General structure of the human SRC-3 
gene (13). Exons are depicted as black bars while introns appear white. Numbers at the top 
indicate positions for the first base pair (bp) of each exon. The first bp of the ATG start codon 
is numbered as 1. Numbers at the bottom indicate the order of exons. Positions of 
translational start (ATG) and stop codons are indicated by arrows 
1.1.3 Molecular structure and functional features of SRCs： 
SRC-3 was identified from an amplified  region on the long arm of chromosome 20 
( 20q12) in breast cancer(8).  Structurally SRC-3 consists on three structural domains 
(Figure 2):  
The amino-terminal region containing a basic helix-loop-helix (bHLH) region and a 
PAS [period (Per), Aryl hydrocarbon receptor (AhR), and single-minded (Sim)](14-17) 
domain is the most conserved region and is required for protein–protein 
interactions(18-19). The bHLH–PAS domain can interact with several transcription 
factors, such as myogenin, myocytespecific enhancer factor 2C (MEF2C) and 
transcriptional enhancer proteins, to potentiate transcription(20-21). 
The central region of the SRC proteins contains multiple LXXLL (where L is leucine 
and X is any amino acid) motifs, which form amphipathic α-helices and are 
responsible for interacting with NRs.  The mutation of key residues in these LXXLL 
motifs of SRC-1 has been shown to abolish interaction and coactivation of the AF-2 
of ER, and distinct LXXLL motifs exhibit differential binding to different receptors.  
The carboxyl terminus contains two transcriptional activation domains (AD1 and 
AD2). AD1 binds CREB-binding protein (CBP) and the histone acetyltransferase 
p300 (also known as EP300), and the recruitment of CBP or p300 by SRCs to the 
chromatin is essential for SRC-mediated transcriptional activation (22-24). AD2 
interacts with co-activator-associated arginine methyl transferase 1 (CARM1) and 
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methyltransferases (25-27). 
The C termini of SRC-1 and SRC-3 possess histone acetyltransferase (HAT) activity 
domain. These findings suggest that SRC coactivators may play a role in chromatin 
remodeling during the process of nuclear receptor-directed initiation of transcription. 
However, it remains unclear how important these SRC HAT activities are for target 
gene activation since the SRC HAT activities might be rather weaker than those in 
CBP, p300 and p/CAF (p300 and CBP-associated factor)(28-29).  
 
Figure 2 : Structural and functional domains of the mouse SRC-3 protein (13). The numbers 
at the top indicate the position in amino acid sequence. The letters within the bar indicate 
structural domains and the lines under the bar indicate functional domains that interact with 
different factors or serve as transcriptional activation domain. bHLH, basic helix–loop–helix 
domain; PAS, Per/ARNT/Sim homologous domain; L, LXXLL alpha-helix motif; S/T, 
serine/threonine-rich region; Q, glutamine-rich domain. 
 
These molecular features provide SRCs with a suitable structural base for recruiting 
additional co-regulators and general transcription factors, which in turn results in 
chromatin remodelling, assembly of general transcription factors and recruitment of 
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In addition to serving as co-activators for NRs, SRCs are co-activators for other 
transcription factors, including nuclear factor-κB (NF-κB), Smads, E2F1, signal 
transducers and activators of transcription (STATs), hypoxia inducible factor 1 (HIF1), 
p53 and pRB (TABLE 1). SRCs can also promote gene transcription by interacting 
with kinases, phosphatases, ubiquitin ligases, small ubiquitin-related modifier (SuMO) 
ligases, histone acetyltransferases and histone methyltransferases (TABLE 1). By 
modulating gene expression that is controlled by a broad range of NRs and non-NR 
transcription factors, SRCs regulate many diverse physiological functions.  The 
molecular targets of SRCs are numerous. Genetic ablation of SRC-1 altered the gene 
expression patterns that are involved in cell cycle and energy metabolism pathways, 
such as glycolysis, glycogen synthesis and fatty acid synthesis (32). Genetic ablation 
of SRC-2 increased gene expression for energy expenditure but decreased gene 
expression for energy storage(32). SRC-3 is required for the expression of several 
genes for the cell cycle and apoptosis in breast cancer cells(33). 
Five alternatively spliced SRC-1 isoforms have been reported(34). In comparison to 
SRC-1a, SRC-1b lacks an N-terminal region, and SRC-1c, SRC-1d and SRC-1e all 
differ from SRC-1a (as well as from each other) at their C termini. It has been shown 
that SRC-1a and SRC-1b have different abilities to increase oestrogen receptor-α 
(ERα; also known as ESR1) activity in cultured cells(35). A SRC-3 isoform, 
SRC-3-Δ3, has also been reported(36). SRC-3-Δ3 lacks the N-terminal bHLH–PAS 
domain and it may be a more active co-activator for ERα and progesterone receptor 
(PR; also known as PRGR) than the full-length SRC-3. However, the in vivo 
expression profiles and physiological significance of these SRC-1 and SRC-3 
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Table 1 : List of proteins that interact with SRCs (37). 
CATEGORY FUNCTIONAL CONSEQUENCE 





















































Phosphorylation and stabilization  
Phosphorylation and activation  
Phosphorylation, activation and degradation  
Phosphorylation and activation 
Phosphorylation and activation 
Dephosphorylation and suppression 
Phosphorylation and activation 
Dephosphorylation and stabilization 
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1.1.4 SRC-3 in cancer： 
SRC-3 amplification and/or overexpression are detected in many hormone-sensitive 
tumors, such as breast, prostate, and ovarian cancer, and meningioma. In breast cancer 
biopsies, SRC-3 is shown to be amplified and overexpressed in 5-10% and 30-60% of 
cases respectively(8, 38). Interestingly, SRC-3 overexpression in breast cancer usually 
correlates with the expression of ERBB2, matrix metalloproteinase 2 (MMP2), 
MMP9 and PEA3, as well as with larger tumour size, higher tumour grade. In 
tamoxifen treated patients, high levels of SRC-3 expression are associated with 
tamoxifen resistance and a poorer DFS (Disease-free survival). Importantly, patients 
with high levels of both SRC-3 and ERBB2 exhibit early and severe resistance to 
therapy with selective oestrogen receptor modulators (39). As ERBB2 activates 
MAPK, which in turn phosphorylates ER and activates SRC-3 , the overexpression of 
both ERBB2 and SRC-3 significantly increases the agonist activity of tamoxifen and 
therefore reduces its anti-tumour activity in patients with breast cancer (40-41) . In 
breast cancer cells, SRC-3 can be recruited to the oestrogen-responsive CCND1 
promoter to increase cyclin D1 expression - depletion of SRC-3 in MCF-7 cells 
significantly reduces oestrogen-mediated cell proliferation and survival. The in vivo 
role of SRC-3 in breast cancer initiation and progression has been investigated in 
multiple mouse models. SRC-3 knockout (SRC-3−/−) mice harboring the 
MMTV/v-Ha-ras transgene (ras+) to evaluate the contribution of SRC-3 to the process 
of mammary gland tumorigenesis. SRC-3−/−/ras+ virgin females showed significantly 
lower incidence and much less extent of mammary gland ductal hyperplasia than 
SRC-3+/+/ras+ virgins, indicating that the initiation of mammary gland tumorigenesis 
induced by the MMTV/v-Ha-ras oncogene was suppressed in SRC-3−/− mice. 
Furthermore, the frequency of breast tumor appearance and the speed of tumor growth 
and metastasis to lung were dramatically reduced in SRC-3−/−/ras+ mice as compared 
to age-matched SRC-3+/+/ras+ mice. These results indicate that the progression of 
breast cancer induced by MMTV/v-Ha-ras is also significantly inhibited in the 
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